logo

For the Inventor, By the Inventor

Oxford, United Kingdom

Vilasben Kanji Shah

This inventor holds 10 USPTO granted patents. Top assignees: Warner-Lambert Company, Prosidion Limited. Active years: 2006-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vilasben Kanji Shah. Retrieved from https://idiyas.com/inventor/vilasben-kanji-shah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 14(Granted Patents)


Location History:

  • Birmingham, GB (2006)
  • Hall Green, GB (2006)
  • Oxford, GB (2007 - 2012)

Company Filing History:

goldMedal6 out of 2,538 
 
Warner-Lambert Company
 patents
silverMedal4 out of 16 
 
Prosidion Limited
 patents

Years Active: 2006-2012

Loading Chart...
10 patents (USPTO):Explore Patents
1. 8193359 - G-protein coupled receptor agonists (2012-06-05),
2. 7745491 - Substituted phenylacetamides and their use as glucokinase activators (2010-06-29),
3. 7582632 - Tri(cyclo) substituted amide compounds (2009-09-01),
4. 7214681 - Tri(cyclo) substituted amide compounds (2007-05-08),
5. 7115745 - Benzyl urea and thiourea derivatives (2006-10-03),
6. 7098340 - Benzyl sulfonamide derivatives (2006-08-29),
7. 7074933 - Urea and thiourea derivatives (2006-07-11),
8. 7064207 - Androgen receptor antagonists (2006-06-20),
9. 7057048 - Androgen receptor antagonists (2006-06-06),
10. 7009052 - Sulfonamide derivatives (2006-03-07),

Title: The Innovative Contributions of Vilasben Kanji Shah

Introduction

Vilasben Kanji Shah is a prominent inventor based in Oxford, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various health conditions. With a total of 10 patents to his name, Shah's work has the potential to impact the treatment of obesity and diabetes.

Latest Patents

Shah's latest patents include innovative compounds that serve as G-protein coupled receptor agonists. These compounds, described as Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are specifically agonists of GPR116 and are useful for treating obesity and diabetes. Another notable patent involves substituted phenylacetamides, which are glucokinase activators. These compounds, also defined by Formula (I) where R is a cycloalkylsulphonyl group, are beneficial in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

Career Highlights

Throughout his career, Shah has worked with reputable companies such as Warner-Lambert Company and Prosidion Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas, leading to the successful patenting of his inventions.

Collaborations

Some of Shah's notable coworkers include Matthew Colin Thor Fyfe and Martin James Procter. Their collaboration has likely contributed to the advancement of research and development in their respective fields.

Conclusion

Vilasben Kanji Shah's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through scientific research. His patents reflect a deep understanding of complex biological mechanisms and a dedication to addressing critical health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…